- Lexaria Bioscience Corp. announced and closed a **$4.0 million registered direct offering** and concurrent private placement on September 29, 2025.  **[1348362_0001640334-25-001742_lxrp_ex991.htm:0]** **[1348362_0001640334-25-001742_lxrp_ex992.htm:0]** **[1348362_0001640334-25-001742_lxrp_8k.htm:2]** 
- The offering included the sale of **2,666,667 shares of common stock at $1.50 per share**.  **[1348362_0001640334-25-001742_lxrp_ex991.htm:0]** **[1348362_0001640334-25-001742_lxrp_ex992.htm:0]** **[1348362_0001640334-25-001742_lxrp_8k.htm:1]** 
- Concurrently, the company issued **2,666,667 unregistered warrants** to purchase common stock, with an exercise price of **$1.37 per share**.  **[1348362_0001640334-25-001742_lxrp_ex991.htm:0]** **[1348362_0001640334-25-001742_lxrp_ex992.htm:0]** **[1348362_0001640334-25-001742_lxrp_8k.htm:1]** 
- The net proceeds from the offering are intended for **working capital and general corporate purposes**, including 2026 R&D and business development plans.  **[1348362_0001640334-25-001742_lxrp_ex991.htm:0]** **[1348362_0001640334-25-001742_lxrp_ex992.htm:0]** **[1348362_0001640334-25-001742_lxrp_ex992.htm:1]** **[1348362_0001640334-25-001742_lxrp_8k.htm:2]**

Lexaria Bioscience Corp. Closes $4.0 Million Registered Direct Offering

- Lexaria Bioscience Corp. announced a registered direct offering to sell approximately **2.67 million shares** of common stock at **$1.50 per share**, expecting to raise about **$4 million** for working capital and general corporate purposes.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- The offering also includes unregistered warrants exercisable at **$1.37 per share**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]**  This follows the termination of a prior sales agreement that had raised only **$38,236**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- Despite facing significant financial challenges, including a **negative operating margin of -1849.84%** and a **3-year revenue decline rate of -39.2%**, Lexaria's shares **surged 32%** in premarket trading.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]** 
- The company maintains a strong balance sheet with a **current ratio of 3.9** and a **low debt-to-equity ratio of 0.02**, and analysts currently rate the stock as a **Buy** with a **$4.00 price target**.  **[1348362_9508d64377f44c5da2972a79eb1dfc0c]**

Lexaria Bioscience (LEXX)